1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow BHT 3009: new trials by email Literature Review of BHT 3009 trials Research Report on BHT 3009
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis BHT-3009 0.5 mg, BHT-3009 1.5 mg, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Bayhill Therapeutics | 252 | 2006-02-01 | 2008-02-11 |
Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Frank Valone, MD (1)